# Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026

- Link: https://www.thailand-business-news.com/pr-news/ascletis-asc36_35fdc-demonstrated-potential-for-once-monthly-to-once-quarterly-dosing-and-robust-weight-loss-in-preclinical-studies-presented-at-easd-2026
- Published: 2026-10-02T16:00:00+07:00
- Author: PR Newswire

|   |

HONG KONG, Oct. 2, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, "Ascletis")
today announced the presentation of key preclinical data for its ASC36_35FDC (ASC36_35
co-formulation) at the 62^(nd) European Association for the Study of Diabetes (EASD)
Annual Meeting, being held September 28–October 2, 2026, in Milan, Italy (EASD 2026).
ASC36_35FDC is a once-monthly to once-quarterly fixed-dose combination injection
of ASC36, a peptide amylin receptor agonist, and ASC35, a peptide GLP-1R/GIPR agonist.
The study was presented in a short oral discussion. The data demonstrated that ASC36_35FDC
exhibited a greater weight-loss trend than eloralintide/tirzepatide or MET-233i/
tirzepatide co-formulations in a diet-induced obesity (DIO) rat model, as well as
excellent formulation stability. Furthermore, once-weekly oral tablet formulation
of ASC36_35FDC has been developed by the Company.

**Key Highlights**

**Robust Weight-Loss: Demonstrating Potential Synergistic Effects in Preclinical
Models**

In both DIO rat and non-human primate (NHP) models, ASC36_35FDC showed greater additional
reductions in body weight and food intake compared with ASC35 monotherapy, suggesting
a potential synergistic effect of the combination.

In the DIO rat model, ASC36_35FDC administered at 5 nmol/kg_8 nmol/kg once every
two days for a total of seven doses demonstrated substantial weight-loss. On Day
14, under the same dosing regimen, body weight decreased by 12.5% with the eloralintide/
tirzepatide co-formulation, 16.8% with the MET-233i/tirzepatide co-formulation, 
and 24.8% with ASC36_35FDC, a 98% and 47% greater relative reduction in body weight,
respectively. Cumulative food intake was also substantially lower in the ASC36_35FDC
group compared to the two comparator groups.

**Excellent Chemical and Physical Stability: No Evidence of Fibrotic Aggregation**

Long-term formulation stability is critical for peptide-based therapeutics. Under
simulated storage conditions (200 rpm, 25°C, 168 hours), no fibril-induced aggregation
was observed for ASC36_35FDC across different concentrations, vehicles, or pH conditions.
In contrast, cagrilintide exhibited substantial fibrotic aggregation under the same
conditions. These findings demonstrate the excellent chemical and physical stability
of ASC36_35FDC and provide a strong foundation for further clinical development 
and potential large-scale manufacturing.

**Pharmacokinetic Profile: Potential for Once-Monthly to Once-Quarterly Dosing**

In NHPs, the pharmacokinetic (PK) profile of ASC36_35FDC was comparable to that 
observed following administration of ASC36 or ASC35 alone. The observed half-life
of ASC36 and ASC35 demonstrated in ASC36_35FDC were as long as 781 hours(approximately
33 days) and 721 hours (approximately 30 days), respectively, supporting once-monthly
and the potential for once-quarterly subcutaneous administration in humans. This
ultra-long-acting profile has the potential to improve treatment convenience and
patient adherence, offering a more convenient therapeutic approach for chronic weight
management.

**Summary and Outlook**

ASC36_35FDC is an internally developed combination therapy leveraging Ascletis’ 
proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD)
and Ultra-Long-Acting Platform (ULAP) technologies. By combining an amylin receptor
agonist with a GLP-1R/GIPR dual agonist, ASC36_35FDC is designed to leverage the
complementary effects of these two therapeutic mechanisms. The preliminary preclinical
data demonstrate promising activity across body-weight reduction, appetite suppression,
formulation stability, and pharmacokinetic properties, supporting the potential 
of ASC36_35FDC as a best-in-class therapeutic candidate.

**About Ascletis Pharma Inc.**

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the 
development and commercialization of potentially best-in-class and first-in-class
therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-
assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (
ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT),
Ascletis has developed multiple drug candidates in-house, including both small molecules
and peptides, such as its lead program, ASC30, a once-daily oral small molecule 
GLP-1R agonist for chronic weight management and diabetes; ASC30_48FDC, a once-daily
oral small molecule dual agonist, a fixed dose combination of ASC30 (GLP-1R agonist)
and ASC48 (GIPR agonist), ASC30_48_39FDC, a once-daily oral small molecule triple
agonist, a fixed dose combination of ASC30 (GLP-1R agonist), ASC48 (GIPR agonist)
and ASC39 (amylin receptor agonist (SARA)), ASC39, an eloralintide-like potent selective
amylin receptor agonist (SARA) once-daily oral small molecule, ASC30_39FDC, a once-
daily oral small molecule dual agonist, a fixed dose combination of ASC30 (GLP-1R
agonist) and ASC39 (amylin receptor agonist (SARA)), ASC36, an amylin peptide, designed
to be administered once monthly to once quarterly subcutaneously and once daily 
orally, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide
agonist, ASC36_35FDC, a once-monthly subcutaneous triple peptide agonist, a fixed
combination of ASC36 (amylin receptor agonist) and ASC35 (GLP-1R/GIPR agonist), 
ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, designed to be administered once
monthly subcutaneously and once daily orally, and ASC36_37FDC, a once-monthly subcutaneous
quadruple peptide agonist, a fixed dose combination of ASC36 (amylin receptor agonist)
and ASC37 (GLP-1R/GIPR/GCGR agonist), for chronic weight management. Ascletis is
listed on the Hong Kong Stock Exchange (1672.HK).

For more information, please visit [www.ascletis.com](https://www.ascletis.com/).

Contact: 
Peter VozzoICR Healthcare443-231-0505 (U.S.)[Peter.vozzo@icrhealthcare.com](https://www.thailand-business-news.com/pr-news/Peter.vozzo@icrhealthcare.com)

Ascletis Pharma Inc. PR and IR Teams
+86-181-0650-9129 (China)[pr@ascletis.com](https://www.thailand-business-news.com/pr-news/pr@ascletis.com)
[ir@ascletis.com](https://www.thailand-business-news.com/pr-news/ir@ascletis.com)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026 ](http://www.prnasia.com/story/archive/5060538_AE60538_0?rand=184833)
